Early Clinical Evaluation of a New Oral Non-Sulfonylurea Hypoglycemic Agent.

Publisher Website
Google Scholar
Abstract
This new agent N1 beta-phenethyl-formamidinyliminourea hydrochloride showed a definite blood sugar lowering effect in 16 of 20 patients. These patients varied in age from 34 to 80 years old and with a duration of diabetes from 1 to 33 years. There were gastrointestinal side effects in 7 of the 20 though no evidence of toxicity has been shown to date. The drug, also known as DBI, has also been shown to be effective in normal and alloxanized animals and is effective in doses as small as 50 - 200 mg daily in humans.

This publication has 3 references indexed in Scilit: